Immunosuppression reduction

DRUG4 trials

Sponsors

Massachusetts General Hospital, Medical University of Vienna, University of Alberta, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

COVID-19ImmunosuppressionKidney Transplant RejectionLiver Transplant

Phase 1

Pilot Trial on Immunosuppression Modulation to Increase SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients

Medical University of ViennaCOVID-19

Start: 2021-11-15End: 2022-11-14Updated: 2022-04-21

Phase 2

Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation

RecruitingNCT07549503

National Institute of Allergy and Infectious Diseases (NIAID)Liver Transplant

Start: 2026-05-14End: 2031-10-01Target: 100Updated: 2026-09-17

Phase 4

Immune Monitoring to Facilitate Belatacept Monotherapy

CompletedNCT04177095

Massachusetts General HospitalImmunosuppression, Kidney Transplant Rejection

Start: 2020-02-11End: 2023-06-01Updated: 2023-12-04

Unknown Phase

Fibroscan to Guide Post Transplant Immunosuppression Minimization

RecruitingNCT07206277

University of AlbertaImmunosuppression

Start: 2025-12-01End: 2028-12-31Target: 50Updated: 2026-01-08